HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICMAD: Small Business Looks To Pull Off Preemption Balancing Act

This article was originally published in The Rose Sheet

Executive Summary

National uniformity in cosmetics regulation remains a top legislative priority for the Independent Cosmetic Manufacturers and Distributors. At the same time, the small business trade association acknowledges that compromise will likely be needed to balance state rights with the streamlined certainty that a strong national standard would provide for industry.

You may also be interested in...



WEN Will Guthy-Renker, Chaz Dean Put Hair-Loss Ordeal Behind Them?

WEN is “new” spelled backwards, but the safety scrutiny facing the hair-care brand is anything but. FDA continues to investigate related adverse-event reports, but 2017 could be the year that Guthy-Renker and Chaz Dean dispense with the lion’s share of consumer complaints and associated payouts.

Wildcard President Trump And The Prospects For Cosmetics Reg Reform

EWG maintains that “the result of the election has no effect whatsoever on the need for cosmetics reform,” but it remains to be seen how legislative proposals for increased oversight would be received by the president-elect, who has outlined plans for dramatically cutting perceived overregulation. Meanwhile, new leadership is likely to be appointed at FDA, and hopes dwindle regarding the Trans-Pacific Partnership.

FDA Questions Constitutionality Of Proposed CIR Bridge, A Blow To CMA Bill

The Cosmetic Modernization Amendments of 2015 is touted by small business as a more appropriately sized update to the regulatory framework than the front-running PCPSA. However, some provisions seen as vital are absent from the bill, while its call for FDA to accept CIR safety decisions could be deemed unconstitutional, an FDA official suggests in a letter to Senate HELP Committee Chair Lamar Alexander.

Related Content

Topics

UsernamePublicRestriction

Register

RS108572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel